366

Angiogenesis, Exudation, and Degeneration 2026 – Virtual Edition
A scientific education

Angiogenesis, Exudation, and Degeneration 2026 – Virtual Edition
A scientific education

 Zum Kalender hinzufügen
 Veranstaltung teilen
 Zur Merkliste hinzufügen
Datum
07.02.2026, 07:50 - 14:10
Sprache
Englisch
Gebühren ab
200.00 USD
Veranstalter
Bascom Palmer Eye Institute
Organisator

Bascom Palmer Eye Institute
1120 NW 14th Street, Suite 1563
US - 33136 Miami, Florida
Tel.: +1 (305) 326 6110

Fax: +1 (305) 326 6518

This Web-Seminar for retina specialists, general ophthalmologists and researchers will review the latest in imaging, translational research, and clinical trials with an emphasis on how these results will impact clinical ophthalmology. It will emphasize early phase clinical trials and recently completed studies focused on the treatment of a wide range of retinal diseases with special emphasis on AMD, diabetic retinopathy, uveitis, and retinal degeneration.
  • Basisinformation
    Datum
    07.02.2026, 07:50 - 14:10
    Sprache
    Englisch
    Gebühren ab
    200.00 USD
    Veranstalter
    Bascom Palmer Eye Institute
    Organisator

    Bascom Palmer Eye Institute
    1120 NW 14th Street, Suite 1563
    US - 33136 Miami, Florida
    Tel.: +1 (305) 326 6110

    Fax: +1 (305) 326 6518

  • Programm

    Course Objectives

    Upon completion of this course, participants should be able to:

    • Understand new evidence for detailing the pathophysiology in nonexudative age-related macular degeneration.
    • Examine new evidence for predicting disease progression in nonexudative age-related macular degeneration.
    • Evaluate the benefits and limitations of different imaging and visual function technologies in the diagnosis and clinical management of macular and retinal diseases.
    • Incorporate the latest advances in artificial intelligence for the diagnosis and management of retinal diseases.
    • Evaluate emerging therapies for the treatment of late nonexudative age-related macular degeneration and review the real-world outcomes following the use of complement inhibitors in clinical practice to better understand the population most likely to benefit from these drugs.
    • Evaluate therapies targeting novel disease pathways being investigated in early-stage clinical trials for nonexudative age-related macular degeneration.
    • Provide an update on anti-VEGF therapies recently approved and currently in development.
    • Appreciate the next generation of therapies for exudative ocular diseases.
    • Evaluate emerging therapies for the treatment of inherited retinal degenerations.

    Agenda

    Saturday, February 7, 2026

    7:50 am Welcome and Overview / Pre-Program Test
    Philip J. Rosenfeld, Harry W. Flynn, Jr., and Thomas A. Albini
      Session I: AMD: Imaging and Disease Progression
    Moderators: Giovanni Gregori, Philip J. Rosenfeld, and Zohar Yehoshua
    Panelists: Christine A. Curcio, Emily Y. Chew, Aaron Y. Lee, Pearse Keane, Viet-Hoan Le, Omar El-Mulki, Ruikang (Ricky) Wang, Yunchan Hwang, Alessandro Berni, and Robyn Guymer
    7:00 Retinal, Plasma, and Dietary Xanthophyll Carotenoids in ALSTAR2
    Christine A. Curcio
    7:10 CART Analyses of OCT Classification of AMD
    Emily Y. Chew
    7:20 Deep Learning for AMD: Latest Advances
    Aaron Y. Lee
    7:30 Building a Database of Patients with Early and Intermediate AMD and Long-Term Follow-Up
    Pearse Keane
    7:40 Characterizing and Detecting Drusen with Hyporeflective Cores in OCT Images
    Viet-Hoan Le
    7:50 Do Calcified Drusen and Drusen with Hypo-reflective Cores Predict Disease Progression from iAMD to Large HyperTDs?
    Omar El-Mulki
    8:00 OCTA Imaging of Choriocapillaris in AMD: Practical Considerations
    Ruikang (Ricky) Wang
    8:10 Choriocapillaris Hemodynamic Impairment in Hypertransmission Defects: VISTA OCTA
    Yunchan Hwang
    8:20 Novel Clinical Trial Designs for Intermediate AMD
    Alessandro Berni
    8:30 Nanosecond Laser Treatment Allows the Progressive Loss of the OCT Outer Retinal Bands in iAMD Eyes Without Coexistent RPD
    Robyn Guymer
      Session II: Photoreceptors and AI in AMD
    Moderators: Omer Trivizki, Jaclyn Kovach, and Philip J. Rosenfeld
    Panelists: SrinVas R. Sadda, Giovanni Staurenghi, Karl Csaky, Amitha Domalpally, Justis P. Ehlers, Ursula Schmidt-Erfurth, Barbara Blodi, David Eichenbaum, Diana V. Do, and Marc Steffen Schmitz-Valckenberg
    8:40 Validation of Photoreceptor Metrics for AMD Using AOSLO
    SriniVas R. Sadda
    8:50 Elipsoid Zone Measurement: Pros and Cons
    Giovanni Staurenghi
    9:00 Further Assessments of Cone Structure – Function in Non-Foveal Geographic Atrophy
    Karl Csaky
    9:10 Methods for Assessing Photoreceptor Loss in GA
    Amitha Domalpally
    9:20 The Impact of Pseudodrusen on Ellipsoid Zone Integrity Measures in Dry AMD
    Justis P. Ehlers
    9:30 Accuracy and Reliability of AI-based Assessment of Ellipsoid Zone (EZ) Loss and Thinning in Geographic Atrophy (GA)
    Ursula Schmidt-Erfurth
    9:40 Use of an AI Algorithm by Retina Specialists in Prescreening GA Patients for Possible Trial Enrollment
    Barbara Blodi
    9:50 Automated Image Aggregation & AI Analysis Combined with Clinical Data (EMR) in Geographic Atrophy for Improved Candidate Selection for Clinical Trials
    David Eichenbaum
    10:00 AI in GA: Learnings from the Pegcetacoplan Clinical Program
    Diana V. Do
    10:10 AI-Powered Prediction of Retinal Function by OCT Imaging in Geographic Atrophy
    Marc Steffen Schmitz-Valckenberg
      Session III: Geographic Atrophy in AMD
    Moderators: Philip J. Rosenfeld, Omer Trivizki, and Jesse Sengillo
    Panelists: Roy Schwartz, Seung-Young Yu, Gemmy Cheung Chui Ming, Giselle Herrera, Sara Beqiri, Caroline Baumal, Glenn J. Jaffe, and David R. Lally
    10:20 A Simplified Severity Scale for GA
    Roy Schwartz
    10:30 Imaging-Based Prediction of Geographic Atrophy Progression Using En Face OCT and FAF
    Seung-Young Yu
    10:40 Incident GA in the Fellow Eye of Patients Presenting with Unilateral Exudative AMD
    Gemmy Cheung Chui Ming
    10:50 Measuring Enlargement Rates of Large Choroidal Hypertransmission Defects over a Wide Range of Lesion Sizes in AMD
    Gissel Herrera
    11:00 The Symmetry of Atrophy Enlargement in AMD Eyes with Bilateral Atrophy
    Sara Beqiri
    11:10 Can Visual Acuity be Estimated from Multimodal Imaging of GA in AMD?
    Caroline Baumal
    11:20 Correlation of Foveal Invasion with Visual Function at Baseline in the Regeneron SIENNA Geographic Atrophy C5 Inhibitor Trial
    Glenn J. Jaffe
    11:30 Controversy in Micronutrient Use in GA
    David R. Lally
      Session IV: Emerging Therapies for Non-Exudative AMD
    Moderators: Nicolas A. Yannuzzi, Philip J. Rosenfeld, and Omer Trivizki
    Panelists: Nancy M. Holekamp, Omer Trivizki, Ivan Lylyk, Mario Saravia, David N. Zacks, Jayakrishna Ambati, Roger A. Goldberg, Arshad M. Khanani, and Frank G. Holz
    11:40 3-D Pre-Clinical Models Support a Perfusion-Based Hypothesis for AMD
    Nancy M. Holekamp
    11:50 Correlations Between Ophthalmic Artery Stenoses and AMD Severity
    Omer Trivizki
    12:00 pm Performing Ophthalmic Artery Angioplasty in a Cohort of Patients with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration (AMD)
    Ivan Lylyk
    12:05 A Feasibility Study of Balloon Angioplasty for the Treatment of Ophthalmic Artery Stenoses in Patients with Geographic Atrophy
    Mario Saravia
    12:10 Fas Inhibition With ONL1204 Ophthalmic Solution for the Treatment of Geographic Atrophy: Results from a Phase 1b Study
    David N. Zacks
    12:15 Inflammasome Inhibition with Kamuvudine K8: A Phase II Clinical Trial in Bilateral Geographic Atrophy
    Jayakrishna Ambati
    12:25 Results from the Phase 2 MAGNIFY TRIAL: Oral Zervimesine for the Treatment of Geographic Atrophy
    Roger A. Goldberg
    12:35 Results from the Phase 2b/3 SIGLEC Trial: AVD-104 in the Management of Geographic Atrophy from Age-Related Macular Degeneration
    Arshad M. Khanani
    12:45 Vision Restoration with the PRIMA System in Geographic Atrophy Due to AMD
    Frank G. Holz
      Session V: FDA-Approved Therapies for the Treatment of Non-Exudative AMD
    Moderators: Thomas A. Albini, Maura Di Nicola, and Philip J. Rosenfeld
    Panelists: Eleonora Lad, Nathan C. Steinle, Lawrence Singerman, Mathew MacCumber, Hasenin Al-khersan, Mengxi Shen, and Philip J. Rosenfeld
    12:55 LIGHTSITE IIIB: An Open-Label, Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Subjects with Dry Age-Related Macular Degeneration
    Eleonora Lad
    1:05 Factors Affecting GA Progression and Vision Loss in OAKS and DERBY Trials
    Nathan C. Steinle
    1:15 24-Month Results from the GALE Open- Label Extension Study: 48 Months of Continuous Pegcetacoplan
    Lawrence Singerman
    1:25 Real-World Visual Acuity and Safety Outcomes from Using Complement Inhibitors for GA in AMD
    Mathew MacCumber
    1:35 Real-World Anatomic Outcomes from Using Complement Inhibitors for GA in AMD
    Hasenin Al-khersan
    1:45 Real-World Efficacy of Pegcetacoplan Over Two Years
    Mengxi Shen
    1:55 Changes in Retinal and Optic Nerve Thickness Measurements Associated with Pegcetacoplan Therapy
    Philip J. Rosenfeld
      Session VI: Imaging, Microperimetry, and Emerging Therapies for Exudative AMD
    Moderators: Lawrence Singerman, Luis J. Haddock, and Philip J. Rosenfeld
    Panelists: Giuseppe Querques, David Sarraf, Usha Chakravarthy, Monika Fleckenstein, Mark R. Barakat, Charles C. Wykoff, Allen C. Ho, Tong (Linda) Li, Arshad M. Khanani, and Rishi P. Singh
    2:05 Fibrogliosis in Age-Related Macular Degeneration: A New Mechanistic Perspective
    Giuseppe Querques
    2:15 Type 4 MNV: A New Addition to the OCT Classification of Neovascular AMD
    David Sarraf
    2:25 Can iRORA and cRORA Definitions be Applied to Detect Macular Atrophy in Treated nAMD: Findings from the 5T BIG Study
    Usha Chakravarthy
    2:35 Retinal Sensitivity Associated with Type-1 Macular Neovascularization
    Monika Fleckenstein
    2:45 OPTIC Trial: Long-Term Outcomes with Ixo-vec in nAMD
    Mark R. Barakat
    2:55 Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular AMD: 2-year Efficacy and Safety Results from the Phase 2 LUNA Study
    Charles C. Wykoff
    3:05 Expanded One Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy Sura-vec (ABBV-RGX-314) for Neovascular AMD
    Allen C. Ho
    3:15 Subretinal LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Results of a Randomized, Active-Controlled Phase 2 Trial
    Tong (Linda) Li
    3:25 Long-Term Follow-Up from the PRISM Study: 4D-150 for the Treatment of Neovascular AMD
    Arshad M. Khanani
    3:35 Retinal Fluid Dynamics and Treatment Durability in nAMD: Insights from the DAVIO 2 Trial
    Rishi P. Singh
      Session VII: Clinical Therapies for Exudative AMD, Diabetic Retinopathy, and Retinal Vascular Diseases
    Moderators: Janet L. Davis, Basil Williams, and Thomas A. Albini
    Panelists: Anat Loewenstein, Mark R. Barakat, Veeral S. Sheth, Carl Danzig, Gemmy Cheung Chui Ming, Dante Pieramici, Peter A. Campochiaro, David M. Brown, and John A. Wells
    3:45 Longitudinal Validation and Real-World Management with Home OCT in Neovascular AMD
    Anat Loewenstein
    3:55 Machine Learning based Volumetric Analysis of nAMD Biomarkers in Tenaya/Lucerne
    Mark R. Barakat
    4:05 12-Month Results from The VOYAGER Study: An Open-Label International Study Using Faricimab in Treatment-Naïve and Previously Treated nAMD and DME Eyes
    Veeral S. Sheth
    4:15 Four-Year Outcomes of Faricimab in nAMD: Safety and Efficacy Results From the AVONELLE-X Long-Term Extension Trial
    Carl Danzig
    4:25 Faricimab for Polypoidal Choroidal Vasculopathy: 1-Year Results from the Phase 3b/4 SALWEEN Trial
    Gemmy Cheung Chui Ming
    4:35 Pagoda End of Study Results: Port Delivery System for the Treatment of Diabetic Macular Edema
    Dante Pieramici
    4:45 Suppression of VEGF-A is Sufficient to Effectively Treat 95% of DME Patients
    Peter A. Campochiaro
    4:55 Safety and Efficacy of Aflibercept 8 mg in Patients With nAMD or DME: Primary Results from the Phase 3b ELARA Trial
    David M. Brown
    5:05 Safety Profile of Aflibercept 8 mg: A Pooled Analysis of the CANDELA, PULSAR, PHOTON, and QUASAR Trials
    John A. Wells
      Session VIII: Diabetic Retinopathy and Macular Telangiectasia Type 2
    Moderators: Harry W. Flynn, Jr., Justin H. Townsend, and William E. Smiddy
    Panelists: Sandy Wenting Zhou, Toshinori Murata, Jennifer K. Sun, Michael S. Ip, Jennifer I. Lim, Carl D. Regillo, Andrew J. Barkmeier, Michael A. Singer, Veeral S. Sheth, Dilsher Dhoot, Baruch Kuppermann, Martin Friedlander, and W. Lloyd Clark
    5:15 AI-Assisted Vascular Biomarker Evaluation in Diabetic Retinopathy On Ultrawide Field Swept-Source Optical Coherence Tomography Angiography - DRIVE Study
    Sandy Wenting Zhou
    5:25 OCTA-Based Analysis of Leakage and Microaneurysms Using Enhanced AI-Inferred Fluorescein Angiography
    Toshinori Murata
    5:35 Association of Retinal Nonperfusion with Vision Threatening Outcomes in Protocol AA
    Jennifer K. Sun
    5:45 Structural OCT Biomarker Responses to Aflibercept, Ranibizumab, and Bevacizumab over 5 years: A Post Hoc Analysis of the DRCR Protocol T
    Michael S. Ip
    5:55 Automated Quantification of the OCT Biomarker Retinal Fluid in Diabetic Macular Edema Treated with Faricimab
    Jennifer I. Lim
    6:05 Danegaptide: A Novel, First-in-Class Oral Therapy for Patients with NPDR - Preclinical and Phase 1b Study Results
    Carl D. Regillo
    6:10 Phase 2 Study Evaluating Short-Term Efficacy of Tonabersat for Diabetic Macular Edema
    Andrew J. Barkmeier
    6:20 Subcutaneous Migaldendranib (MGB) for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration: 40-Week Study Results from a Phase 2 Clinical Trial
    Michael A. Singer
    6:30 PER-001: A Long-Acting Intravitreal Endothelin Antagonist for Structural and Functional Improvement in Diabetic Retinopathy
    Veeral S. Sheth
    6:40 Suprachoroidal Delivery of Surabgene Lomparvovec (Sura-vec, ABBV-RGX-314): 2-Year Results in Non-Proliferative Diabetic Retinopathy
    Dilsher Dhoot
    6:50 Efficacy and Safety Outcomes with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema from the DIAMOND Stage 1 Phase 2/3 Trial
    Baruch Kuppermann
    7:00 What's New with MacTel 2?
    Martin Friedlander
    7:10 Timing of Ocular Adverse Events in Pooled Analysis of Two Phase 3 Trials of Revakinagene Taroretcel-Iwey (NT-501) in MacTel Type 2
    W. Lloyd Clark
      Session IX: Inherited Retinal Degenerations
    Moderators: Byron L. Lam, Sander R. Dubovy, and Ninel Z. Gregori
    Panelists: Robert Bhisitkul, David S. Boyer, Peter K. Kaiser, Kenneth C. Fan, Nadia K. Waheed, Byron C. Lam, and Fenghua Wang
    7:20 Phase 1 WALLABY/PLATYPUS Studies of Intravitreal VP- 001 in PRPF31 Mutation-Associated Retinal Pigmentosa
    Robert Bhisitkul
    7:25 Ray Therapeutics Phase 1 Trial of Optogenetics for Retinitis Pigmentosa
    David S. Boyer
    7:35 LUCE: A First-in-Human Phase I/II Trial of Dual AAV8.MYO7A Gene Therapy in Subjects with Usher Syndrome Type1B Retinitis Pigmentosa
    Peter K. Kaiser
    7:45 The TEASE Program: Evaluating Gildeuretinol in Early to Advanced Stages of Stargardt Disease
    Kenneth C. Fan
    7:55 Clinical Trial and Imaging Results of a Phase 2 Study on RPGR Gene Therapy in X-Linked Retinitis Pigmentosa
    Nadia K. Waheed
    8:05 Safety and Efficacy of MCO-010 Phase 2 Optogenetic Therapy in Patients with Stargardt Disease
    Byron C. Lam
    8:15 Safety and Efficacy of LX101 Gene Therapy in Chinese Patients with RPE65-Inherited Retinal Dystrophy: Results of the Phase 3 Trial
    Fenghua Wang
    8:25 Post-Program Test and Closing Remarks
    8:30 Meeting Adjourns
  • Gebühren
    Fachärzte/-innen
    Gebühren ab
    200,00 USD
    Ärzte/-innen in Weiterbildung
    Gebühren ab
    200,00 USD
    All registrations must be received no later than Thursday, February 5th, 2026 at 3:00 pm (ET).
  • Buchung / Anmeldung

    Registration required. Please contact the organizer for further information.

  • Zertifizierung
    Zertifizierung beantragt für CME Punkte bei der Sonstige
    The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 13.0 AMA PRA Category 1 Credits™.

Veranstaltung teilen

Kontakt zu EYEFOX

+49 (30) 4036 422 - 0

info@eyefox.com